Lansen's second share reduction plan of Starry

Cathay International Holdings Limited

("Cathay", the "Company" or the "Group")

Lansen's second share reduction plan of Starry

Hong Kong, 19 September 2017 - Cathay International Holdings Ltd. (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, today announces that, Lansen Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), the Company's 50.56% owned subsidiary, has made a regulatory announcement in accordance with the requirements of its Hong Kong listing.

Lansen has announced about the second share reduction plan (the "Second Share Reduction Plan") in relation to its holding in the shares of Zheijang Starry Pharmaceutical Co., Ltd. ("Starry") ("Lansen Announcement"). The full text of the Lansen Announcement can be found at http://www.hkexnews.hk/listedco/listconews/SEHK/2017/0919/LTN20170919233.pdf and will also be made available at the Announcements & Notices section of Lansen's homepage at http://holding.lansen.com.cn//en/newslist.aspx?NodeCode=10002000700050005.

It is stated in the Lansen Announcement that Lansen HK has notified Starry of the Second Share Reduction Plan, the key points of which are as follows:

• Number of Starry Shares to be disposed: not more than 5,500,000 Starry Shares, representing not more than 4.583% in Starry.

• Share reduction period: a period commencing on the third trading day of the Shanghai Stock Exchange immediately following 20 September 2017, the date of Starry's announcement of the Second Share Reduction Plan (or a period commencing on the 15th trading day of the Shanghai Stock Exchange immediately following 20 September 2017 for reduction of Starry Shares through centralised competitive bidding system on the Shanghai Stock Exchange) to 8 March 2018.

• Methods of share reduction: through (a) block trade sales, or (b) centralised competitive bidding system on the Shanghai Stock Exchange, provided that total amount of share reduction through block trade sales and the centralised competitive bidding system in any consecutive three months period shall not exceed 2% and 1% of the total number of issued shares in Starry respectively.

• Share reduction price: with reference to the prevailing trading price of Starry Shares on the Shanghai Stock Exchange

It is stated in the Lansen Announcement that, as at the date of the Lansen Announcement, no definitive or legally binding agreement relating to disposal of Starry Shares has been entered into by Lansen or Lansen HK.

Further announcements will be made as appropriate, including any necessary updates in relation to the Company's obligations as an issuer whose shares are quoted on the Main Market of the London Stock Exchange.

-ENDS-

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director) Tel: +852 2828 9289

Patrick Sung (Director and Controller)

Consilium Strategic Communications

Mary-Jane Elliott/ Matthew Neal / Lindsey Neville Tel: +44 (0) 203 709 5700

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

About Lansen

Lansen, whose shares are listed on the mainboard of the Hong Kong Stock Exchange, is a 50.56% owned subsidiary of Cathay. Lansen is engaged in the manufacture, distribution and development of specialty prescription drugs for treatment of autoimmune disorder in rheumatology and dermatology. Lansen is in the leading market position in disease modifying anti-rheumatic drugs ("DMARDs") for treatment of rheumatoid arthritis ("RA") in the PRC. Lansen has established an extensive distribution network, covering more than 1,000 hospitals in four municipalities, 25 provinces and cities in the PRC. For more information please visit the Lansen's website: http://www.lansen.com.cn/en/index.aspx.

About Starry

Starry, whose shares are listed on the Shanghai Stock Exchange (stock code 603520), is 12.65% owned by Lansen. Starry is specialised in the research and development, manufacture, marketing and sales of bulk pharmaceuticals and intermediates. One of the core products of Starry is iohexol for X-CT non-ionic contrast agents. Starry is the largest iohexol manufacturer in the PRC and is experienced in the production management and quality control of bulk pharmaceuticals. For more information please visit Starry's website: http://www.starrypharm.com/en/index.aspx.